Question? Call us
212-363-7500Expired
Lead Plaintiff Deadline
Jan 1, 1800
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
The filed complaint alleges that Qiagen N.V made materially false and/or misleading statements and/or failed to disclose that: During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: “You will see QuantiFERON picking up in Q2 … accelerating to achieve … between 6% and 7% growth” in 2026. He noted Qiagen’s projections remained “perfectly aligned with the target that we gave during our Capital Market Day in June 2024.” On April 28, 2026, Qiagen walked back on these claims and CFO Roland Sackers revealed the disappointing guidance: sales were now projected to “continue at a largely unchanged level from the second quarter of 2025,” and investors would have to wait for QuantiFERON to “return to a more normalized growth rate in 2027.”
In order to be eligible to join the QGEN class action lawsuit, you must have incurred a loss on shares of Qiagen N.V. purchased during the class period listed above.
If you suffered a loss in Qiagen N.V. during the relevant time frame or pursuant to the relevant offering(s), you have until January 1, 1800 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP